Although these data could serve as a rationale for clinically testing BCMA CAR + MT-SLP-76, it is important to note that BCMA may also be expressed at lower levels on the basal ganglia, which may be the cause of a Parkinson’s-like movement disorder observed in selected individuals treated with BCMA CAR T cells33,34. Here, TNFRSF17 is linked to movement disorder.